Anavex has released promising results from a phase 2b/3 clinical trial evaluating its investigational drug, blarcamesine, for early Alzheimer’s disease. The study, conducted across multiple centers, revealed significant reductions in amyloid-ß biomarkers, a critical indicator of Alzheimer’s progression. The trial enrolled 508 participants, with 338 receiving blarcamesine and 170 on placebo. Over 48 weeks, the […]
Day: September 2, 2024
Mark Lamberti: The Architect of Business Evolution
Mark Lamberti is widely recognized within the business community for his significant contributions to the corporate landscape. His career spans decades, showcasing a blend of strategic vision and robust leadership. As a key figure in South African business, Lamberti’s influence extends across multiple industries, from retail to logistics. Lamberti first made headlines as the driving […]